GlassScriptPhysician profile
Lila Tarmin
NPI 1669466108
$5,453.88
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,396 · 2020: $616 · 2021: $1,248 · 2022: $936 · 2023: $518 · 2024: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,485.94 | 2019-2024 | Rinvoq, Skyrizi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $677.90 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $447.72 | 2019-2024 | Stelara, Tremfya |
| Ironwood Pharmaceuticals, INC | $307.51 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.74 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $170.01 | 2019-2024 | |
| Qol Medical, LLC | $139.55 | 2019-2021 | |
| Braintree Laboratories, INC. | $120.58 | 2019-2024 | Suflave, Sutab |
| Pfizer INC. | $106.93 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $103.37 | 2019 | |
| Celgene Corporation | $88.70 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $86.14 | 2019-2022 | |
| Amgen INC. | $60.68 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $56.37 | 2021-2022 | |
| Endogastric Solutions, INC | $47.80 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.76 | 2024 | |
| Merck Sharp & Dohme LLC | $44.39 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $30.35 | 2020-2021 | |
| Redhill Biopharma INC. | $30.08 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $28.34 | 2023 | |
| Evoke Pharma, INC. | $25.86 | 2020-2021 | |
| Medtronic, INC. | $20.74 | 2021 | |
| Ucb, INC. | $19.93 | 2019 | |
| Echosens North America, INC. | $19.00 | 2019 | |
| Dova Pharmaceuticals | $16.90 | 2019 | |
| Ardelyx, INC. | $15.35 | 2024 | Ibsrela |
| Shire North American Group INC | $14.26 | 2019 | |
| Organon LLC | $13.71 | 2021 | |
| Allergan, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lila Tarmin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.